Clinical trial · Observational
Genetics of Prostate Cancer in Young Patients
NCT06714227CI-TRIAL-00083214ProK55completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to identify genetic variants in genes responsible or potentially responsible for the etiology of prostate cancer in a population of patients with early onset of the malignancy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Carcinoma | Prostate Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Molecular analysis of genomic DNA (exome sequencing) from peripheral blood sample | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients diagnosed with prostate carcinoma before the age of 55
- description
- Exome sequencing (WES) of genomic DNA
- interventionNames
- Genetic: Molecular analysis of genomic DNA (exome sequencing) from peripheral blood sample
Primary outcomes (1)
- measure
- Presence/absence and type of pathogenic/probably pathogenic germline variants in genes previously implicated in prostate cancer etiology
- timeFrame
- 4 years
- description
- molecular analysis of genomic DNA
Secondary outcomes (1)
- measure
- Presence/absence and type of variants in genes potentially implicated in the etiology of prostate cancer (candidate genes).
- timeFrame
- 4 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologic or cytologic diagnosis of prostate cancer * Age ≥18 years and ≤55 years at first diagnosis of prostate carcinoma * Availability of clinical and instrumental data related to prostate cancer * Patients who knowingly express willingness to participate in the study after signing written informed consent Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.